| Target Price | ¥5,564.10 |
| Price | ¥5,338.00 |
| Potential |
4.24%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Kobayashi Pharmaceutical 2026 .
The average Kobayashi Pharmaceutical target price is ¥5,564.10.
This is
4.24%
register free of charge
¥7,035.00
31.79%
register free of charge
¥4,949.00
7.29%
register free of charge
|
|
| A rating was issued by 12 analysts: 5 Analysts recommend Kobayashi Pharmaceutical to buy, 7 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Kobayashi Pharmaceutical stock has an average upside potential 2026 of
4.24%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 165.60 | 167.15 |
| 4.53% | 0.93% | |
| EBITDA Margin | 17.93% | 15.46% |
| 7.33% | 13.80% | |
| Net Margin | 6.08% | 7.07% |
| 48.15% | 16.30% |
8 Analysts have issued a sales forecast Kobayashi Pharmaceutical 2025 . The average Kobayashi Pharmaceutical sales estimate is
This results in the following potential growth metrics:
8 Kobayashi Pharmaceutical Analysts have issued a net profit forecast 2025. The average Kobayashi Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 135.42 | 159.01 |
| 49.50% | 17.42% | |
| P/E | 33.14 | |
| EV/Sales | 2.01 |
8 Analysts have issued a Kobayashi Pharmaceutical forecast for earnings per share. The average Kobayashi Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Kobayashi Pharmaceutical...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


